Author Archives: Warren Woessner

Patenting Vaccines – A Look Back and the Road Ahead

On May 21 at 11 a.m. Central, four senior members of Schwegman Lundberg & Woessner’s Chem/Biotech Group will present a new webinar. Drs. Warren D. Woessner, Janet E. Embretson, Monique Perdok and Robin A. Chadwick will review patenting opportunities and … Continue reading

Posted in Conferences and Classes, Webinar | Tagged | Leave a comment

IPO Chat Channel: Inequitable Conduct – A Refresher & Update – April 23rd

Have findings of inequitable conduct due to egregious misconduct become more common post-Therasense or can a simple failure to disclose material prior art still lead to a finding of inequitable conduct? What are the possible consequences to both litigators and … Continue reading

Posted in Inequitable Conduct/Rule 56, Prior Art, Uncategorized | Tagged , , | Leave a comment

CardioNet v. Infobionics: The Requirement for Improvements in Patent Eligibility

This decision, Appeal No. 2019-1149 (Fed. Cir. April 17th 2020) should have required about 13 pages and could have ended after the first paragraph under Section A. Instead, a split panel required a 23 page majority decision and a 10 … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment

BASF Corp. v SNF Holding Co: Section 102 Dissected

In BASF Corp. v. SNF Holding Co, Appeal No. 2019-1243 (Fed. Cir., April 8 2020), a Fed. Cir. panel of Judges Lourie, Moore and Chen – Lourie writing—reviewed the district court’s holding that a BASF patent (U.S. Pat. No. 5,663,329) … Continue reading

Posted in Anticipation, s.102 | Tagged | Leave a comment